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Introduction: UEV1A encodes a ubiquitin-conjugating enzyme variant (Ubc13), which is required for Ubc13-catalyzed
Lys63-linked polyubiquitination of target proteins and nuclear factor κB (NF-кB) activation. Previous reports have
correlated the level of UEV1A expression with tumorigenesis; however, the detailed molecular events leading to
tumors particularly breast cancer and metastasis are unclear. This study is to investigate roles of different UEV1 splicing
variants, and its close homolog MMS2, in promoting tumorigenesis and metastasis in breast cancer cells.
Methods: We experimentally manipulated the UEV1 and MMS2 levels in MDA-MB-231 breast cancer cells and
monitored their effects on cell invasion and migration, as well as tumor formation and metastasis in xenograft mice.
The underlying molecular mechanisms leading to metastasis were also examined.
Results: It was found that overexpression of UEV1A alone, but not UEV1C or MMS2, is sufficient to induce cell invasion
in vitro and metastasis in vivo. This process is mediated by NF-κB activation and requires functional Ubc13. Our
experimental data establish that among NF-κB target genes, UEV1A-regulated matrix metalloproteinase-1
(MMP1) expression plays a critical role in cell invasion and metastasis. Interestingly, experimental depletion of UEV1 in
MDA-MB-231 cells reduces MMP1 expression and prevents tumor formation and metastasis in a xenograft mouse
model, while overexpression of MMP1 overrides the metastasis effects in UEV1-depleted cells.
Conclusions: These results identify UEV1A as a potential therapeutic target in the treatment of metastasic breast
cancers.Introduction
UEV1, also known as CROC1 [1] or CIR1 [2], encodes a
ubiquitin (Ub)-conjugating enzyme variant (Uev) [3]. It was
also identified as a mammalian homolog of yeastMMS2 [4]
and as a co-factor of Ubc13 [5]. Indeed, a Uev (Uev1A or
Mms2) is absolutely required for Ubc13-mediated Lys(K)
63-linked polyubiquitin chain assembly [5-9]. Despite their
shared biochemical activity, Mms2 and Uev1A appear to
function differently in mammalian cells: Ubc13-Mms2 is
required for DNA-damage responses whereas Ubc13-
Uev1A is involved in nuclear factor κB (NF-κB) activation
[10]. Previous studies implicate UEV1 as a potential proto-* Correspondence: wei.xiao@usask.ca
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unless otherwise stated.oncogene. UEV1 was initially identified as a transactivator
of the c-fos promoter [1]. It is downregulated when HT29-
M6 colon cancer cells undergo chemical-induced differenti-
ation, and upregulated when Simian virus 40-transformed
human embryonic kidney cells become immortal [2]. Fur-
thermore, UEV1 is variably upregulated in all tumor cell
lines examined [4], and maps to chromosome 20q13.2 [3],
a region where DNA amplification is frequently reported in
breast cancers [11-14] and other tumors [15], as well as in
virus-transformed immortal cells [16].
Ubc13-Uev1A is involved in NF-κB activation
[10,17,18] and inhibits stress-induced apoptosis in
HepG2 cells [19]. Very recently, it was reported that a
small-molecule inhibitor of Ubc13-Uev1A interaction
can inhibit proliferation and survival of diffuse large B-
cell lymphoma cells [20]. These observations collectively. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and tumorigenic potential; however, whether UEV1 plays
a role in promoting tumorigenesis or progression and
how this is accomplished remains to be elucidated.
NF-кB is a sequence-specific transcription factor known
to be involved in innate immunity, anti-apoptosis and in-
flammation [21-23], and its uncontrolled activation is asso-
ciated with several types of cancers including breast cancer
[24,25]. It regulates a panel of genes that collectively play
pro-survival and anti-apoptotic roles [26,27]. It also controls
the expression of genes linked with invasion, angiogenesis,
and metastasis of cancer, including the matrix metallopro-
teinase (MMP) family [28,29] and chemokine (C-X-C motif)
ligand (CXCL) family genes [30,31]. Activation of NF-κB is
a tightly regulated event. In normal cells, NF-κB becomes
activated only after the appropriate stimulation, and then it
upregulates the transcription of its target genes [24]. NF-κB
is activated by many divergent stimuli, including proinflam-
matory cytokines such as TNF-α, IL-1b, epidermal growth
factor (EGF), T- and B-cell mitogens and bacterial lipopoly-
saccharides (LPS) [32]. Previous studies reported that the
Uev1A-Ubc13 heterodimer is involved in TNF receptor-
associated factor 6 (TRAF6) [17,33] and TRAF2-mediated
[34] activation of NF-κB, in which Ubc13-Uev1A probably
serves as a unique Ubc/E2 along with TRAF proteins to
polyubiquitinate NF-κB essential modulator/inhibitor of κB
proteinkinase (NEMO/IKKγ) [18,35] and/or Rieske iron-
sulfur polypeptide 1(RIP1) [36] to activate IκB kinase (IKK).
Activated IKK leads to the phosphorylation and degradation
of IκBα, resulting in the release of NF-κB RelA (p65) sub-
units to translocate into the nucleus [37].
In this study we demonstrate that in MDA-MB-231 breast
cancer cells, the UEV1A transcript level is moderately ele-
vated compared to normal breast cells. Overexpression
of UEV1A alone in MDA-MB-231 cells is sufficient to
activate NF-кB, which in turn upregulates the MMP1
expression to enhance breast cancer cell metastasis. More
importantly, experimental depletion of Uev1 in MDA-MB-
231 cells reduces MMP1 expression and reduces their abil-
ity to grow tumors and metastasize in a xenograft mouse
model. These observations provide the experimental and
theoretical cornerstone for therapeutic targeting of Uev1A
in the treatment of metastatic breast cancers.
Methods
Cell culture
Human breast cancer cell lines MDA-MB-231, MCF7,
MDA-MB-468, MDA-MB-361, MDA-MB-453, MDA-MB-
436 and SK-BRIII were obtained from the American Type
Culture Collection (ATCC, Manassan, VA, USA). The cells
were cultured in Dulbecco’s minimum essential medium
(DMEM) (Invitrogen, Burlington, ON, Canada) supple-
mented with 10% fetal bovine serum, 100 units/ml penicil-
lin, and 100 μg/ml streptomycin (Invitrogen) in a 5% CO2atmosphere at 37°C. The MCF10A immortalized human
mammary epithelial cells were obtained from ATCC and
cultured in DMEM/F12 medium supplemented with 10%
horse serum, 100 units/ml penicillin, 100 μg/ml strepto-
mycin (Invitrogen), 10 μg/ml insulin (Sigma, St. Louis, MO,
USA), 100 ng/ml choleratoxin (Sigma), 0.5 mg/ml hydro-
cortisone (Sigma), and 20 ng/ml EGF (Peprotech). MDA-
MB-231-TR stable cell lines were created by transfecting
MDA-MB-231 cell lines with pLenti6-TR-lentivirus (Invi-
trogen) and selecting with 10 μg/ml blasticidin (Invitrogen).
Plasmids and pLentivirus vector preparation
Human MMS2, UEV1A, and UEV1C open reading frames
(ORFs) were PCR-amplified as KpnI-XhoI fragments and
cloned into the pcDNA4.0/TO/HA(+) plasmid vector.
The 1.9-kb human MMP1 promoter sequence [GenBank:
AJ002550.1] was PCR-amplified as a KpnI-HindIII fragment
and then cloned into the same sites of pGL4.2 (Invitrogen).
The NF-кB target site was subsequently mutated by site-
directed mutagenesis using a quick-exchange method
(Stratagene, La Jolla, CA, USA). The sense primer for creat-
ing the NF-кB binding site mutation is 5′-AAAGG CAGAA
GGGAA CCTCA AGAGG TTTTG AAGAG CCACC
GTAAA GTGAG-3′ (mutated sequence italicized). The
mutated Ubc13-binding site (F38E) in Uev1A was designed
based on a previous study with Mms2-F13E [9]. The modi-
fied sequence for UEV1 small hairpin RNA (shRNA)
delivered by lentiviral particles was from Santa Cruz Bio-
technology, Inc (Dallas, Texas, USA). The lentiviral particle
infection of breast cancer cells was performed following in-
structions of the supplier. The MMP1 and MMP9 small
interfering RNAs (siRNAs) were purchased from Gene-
pharma Co Ltd (Shanghai, China). The sequence for MMP1
siRNA is 5′- GCGUGUGACAGUAAGCUAATT-3′ and
that for MMP9 siRNA is 5′-CGCUCAUGUACCC
UAUGUATT-3′.
RNA preparation and real-time RT-PCR (qRT-PCR)
Total RNA was prepared from cultured breast cancer cells
by using TRIzol reagent (Invitrogen). First-strand cDNA was
synthesized from total RNA with SuperScript (Invitrogen)
according to manufacturer’s instructions. The human
breast cancer cDNAs TissueScan™ cancer qPCR Arrays
(#BCRT102) were purchased from Origene (Beijing,
China). The clinical information is shown on the website
[38] and Additional file 1. qRT-PCR analysis was per-
formed on the iQ5 cycler (Bio-Rad, Hercules, CA, USA).
The specific primer sets were as follows: GADPH, 5′-
GAAGGTGAAGGTCGGAGTC-3′ and 5′- GAAGATGG
TGATGGGATTTC-3′; UEV1, 5′- TCTCCACAGCAATC
CTATGAGGTTGA-3′ and 5′- CCAACAGTCGGAAAT
TGCGAGGG-3′; UEV1A, 5′- GAGAGGTTCAAGCGT
CTTACCTGAA-3′ and 5′-ACTGTGCCATCTCCTACT
CCTTTCT -3′; UEV1C, 5′-GCAGCCACCACGGGC
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3′; MMS2, 5′- CGCTTGTTGGAAGAACTTGA-3′ and
5′- CGGAGGAGCTTCTGGGTAT-3′; MMP1 5′- AAAT
GCAGGAATTCTTTGGG-3′ and 5′-ATGGTCCACATC
TGCTCTTG-3′; MMP9 5′-CATCGTCATCCAGTTTG
GTG-3′ and 5′- TCGAAGATGAAGGGGAAGTG-3′.
The relative expression levels were calculated using the
comparative cycle threshold (CT) method (2-ΔCT) on the
Bio-Rad iQ5 (Bio-Rad).
Luciferase reporter assay
Cells were seeded in 24-well plates at a density of 1 × 105.
After 24 hr, the cells were transfected using X-tremeGENE
HP DNA Transfection Reagent (Roche, Indianapolis, IN,
USA). Briefly, luciferase reporter gene constructs (400 ng),
pcDNA-Uevs plasmids (400 ng) and the pRL-SV40
Renilla luciferase construct (5 ng) (for normalization)
were co-transfected into the wells. Cell extracts were pre-
pared 48 hr after transfection and the luciferase activity
was measured using the Dual-Luciferase reporter assay
system (Promega, Madison, WI, USA).
Western blot analysis
Cells were grown to log phase and lysed in Dulbecco’s PBS
(150 mM NaCl, 10 mM Na2HPO4 and 10 mM NaH2PO4,
pH 7.4) with 1% SDS and the protease inhibitor cocktail for
mammalian cells (Sigma-Aldrich). Total protein concentra-
tion was determined by the Bradford method using a com-
mercial reagent from Bio-Rad. Cell extracts or purified
proteins were electrophoresed in 10% or 15% SDS-
polyacrylamide gel electrophoresis (PAGE) gels, transferred
to polyvinyl difluoride (PVDF) membrane, and incubated
with specific primary antibodies. Monoclonal antibodies
(mAbs) LN2B (anti-Uev1) and 4E11 (anti-Ubc13) were
from the laboratory stock [10,39]. Primary antibodies
against HA (sc-7392), MMP1 (sc-30069), NF-κB (sc-372),
Lamin B (sc-166729), β-tublin (sc-6216), and secondary
goat anti-mouse antibody IgG-horseradish peroxidase
(HRP) (sc-2005) and goat anti-rabbit IgG-HRP (sc-2004)
antibody were from Santa Cruz. The P-IκBα antibody
(#2859S) was from Cell Signaling Technology (Whitby,
ON, Canada), while an anti-MMP9 antibody (ab38898)
was from Abcam (Toronto, ON, Canada) and β-actin anti-
body (BM0627) was from Boster (Wunah, China).
Immunoprecipitation
We immunoprecipitated 1 mg of protein samples in a total
volume of 1 ml with 2 μg of antibody and 20 μl of Protein-
A beads (for rabbit polyclonal antibodies) or Protein-G
beads (for mouse monoclonal antibodies). The samples were
rotated at 4°C overnight. The beads were washed 4 times
with 1 ml of cold NP40 lysis buffer containing protease in-
hibitors. The beads were then boiled for 10 minutes in the
presence of 25 μl 2 × sample buffer and the released proteinsfractionated by SDS-PAGE in 12% or 15% gels. Proteins
were detected by immunoblotting as described above.
Cell invasion and migration assays
In vitro invasion assays were conducted using Transwells
(Costar, Cambridge, MA, USA) with 8-μm-pore-size poly-
carbonate membrane filters in 24-well culture plates. The
upper surface of the filter was coated with Matrigel
(Becton Dickinson, Bedford, MA, USA) in a volume of
12.5 μl per filter. The Matrigel was dried and reconstituted
at 37°C into a solid gel on the filter surface. The lower
surface of the filter was coated in fibronectin (20 μg/ml),
vitronectin (10 μg/ml), collagen IV (50 μg/ml), or 10%
(BSA)-DMEM as chemoattractants. After starving in BSA-
free DMEM overnight, 2 × 104 cells were seeded in the
upper chamber. The cells were allowed to invade for 48 hr.
Cells that invaded the lower surface of the filter were
counted in five random fields under a light-microscope at
high magnification. Experiments were conducted at least
in triplicate. The in vitro cell migration ability was detected
by wound healing assay or transwell assay without Matrigel
coating. The wound healing assay was performed by seed-
ing 2 × 105 cells onto 96-well plates. Confluent monolayers
were wounded using a pipette tip. After 48 hr the cell mi-
gration distance was measured under a light-microscope at
high magnification in at least three random fields. The
transwell assay without Matrigel was conducted using
Transwells with 8-μm-pore-size polycarbonate membrane
filters in 24-well culture plates. The lower surface of the fil-
ter was coated with 10% BSA-DMEM as chemoattractants.
After starving in a BSA-free DMEM medium overnight,
5 × 104 cells were seeded in the upper chamber. Cells were
allowed to invade for 6 to 36 hr and those migrated to the
lower surface of the filter were counted in five random
fields under a light-microscope at high magnification. Ex-
periments were conducted at least in triplicate.
Metastasis assay in a xenograft mouse model
The experimental mouse work followed the animal care
protocol CNUAREB-2012002 approved by the Capital Nor-
mal University Animal Research Ethics Board and was con-
ducted at the Peking University Health Science Center,
China. For the tumorigenesis assays, 5 × 106 breast cancer
cells were injected subcutaneously into the lateral flanks of
4- to 5-week-old BALB/c female nude mice. The palpable
tumor diameters were measured once per week. Tumor
length (L) and width (W) were measured with a caliper, and
the volume (V) was calculated by the following equation:
V ¼ LW2 =2:
The mice were sacrificed 6 weeks after cell injection. For
experimental metastasis assays by intravenous (i.v.) injection,
2 × 105 breast cancer cells were injected into the tail veins of
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assays were conducted 5 weeks after injection. Metastatic
lung nodules 0.5 mm in diameter were counted. Analysis
of variance (ANOVA) was used for statistical analyses. To
ensure representative sampling of lung tumor nodules,
four sections were made per lung at various depths along
the coronal plane of the lung. The nodules per lung (four
sections) were counted under a light-microscope.
Histopathology
Formalin-fixed lungs were paraffin-embedded, and tissue
sections derived from tumor nodules or other tissues were
stained with H&E to evaluate the morphology and inva-
siveness of breast cancer cells. Metastatic tumor nodules
were counted throughout the entire lung section at all
three depths under a light-microscope. Anti-Uev1A (LN1),
anti-MMP1 (sc-30069) and NF-κB p65 (sc-372) primary
antibodies from Santa Cruz were used for immunohisto-
chemistry (IHC). TissueFocus™ breast cancer tissue micro-
arrays (CT565863) for IHC were obtained from Origene
(Beijing, China). Microscopic images were captured by a
SPOT digital camera mounted in a light-microscope.
Preparation of nuclear fraction
HeLa cells were treated with 40 ng/ml TNF-α for 2 hr.
Cells were washed, scraped with PBS, and centrifuged at
3,000 rpm at 4°C. The pellet was suspended in 10 mM
Tris (pH 8.0) with 1.5 mM MgCl2, 1 mM dithiothreitol,
and 0.1% NP-40, and incubated on ice for 15 minutes. Nu-
clei were separated from cytosol by centrifugation at
12,000 rpm at 4°C for 15 minutes. The cytosolic superna-
tants were removed and the precipitated pellets were sus-
pended in 10 mM Tris (pH 8.0) containing 100 mM NaCl
and stored on ice for 30 minutes. After agitation for 30 mi-
nutes at 4°C, the lysate was centrifuged at 12,000 rpm for
15 minutes at 4°C, and the supernatant was collected.
Electrophoretic mobility shift assay (EMSA)
The secquence of biotin-labelled sense NF-κB probe for
EMSA is 5′-GAACCTCAGAGAACCCCGAAGAGCC-
3′. The cold probe is the same NF-κB sequence without
biotin label. The sequence of biotin-labelled mutated
sense NF-κB probe is 5′-GAA CCTCA AGAGGTTTTG
AAGAGCC-3′ (mutated sequence underlined): 1 ng of
the probe was incubated together with 10 to 20 μg of
cell extracts or 5 to 10 μg of nuclear extracts for 30 mi-
nutes at 25°C in a final volume of 20 μl. The binding
reaction was subsequently separated on a 5.5-7% poly-
acrylamide gel in 1x Tris-Borate-EDTA (TBE) buffer (90 mM
Tris, 90 mM boric acid).
Statistical analysis
The statistical significance of differential findings between
the experimental and control groups was determined byStudent’s t-test as implemented by Microsoft Excel 2010
(*P <0.05, **P <0.01 and ***P <0.001).
Results
Alternative UEV1 transcript levels in breast cancer cell
lines and samples
Two major human UEV1 transcripts (UEV1A and UEV1B)
were previously reported [1]. It was determined that only
Uev1A, but not Uev1B, is able to physically interact with
Ubc13 and promote K63-linked polyubiquitination [10]. It
turns out that Uev1B is excluded from the nucleus and in-
volved in endosomal trafficking [40]. Interestingly, data-
base analyses also indicate another splicing variant that
would encode a 147-amino acid Uev1 core domain, which
we name Uev1C (Figure 1A), the cellular function of which
is currently unknown.
Western blot analysis of endogenous Uev1s using a
Uev1-specific monoclonal antibody LN2B [39] could only
detect Uev1C in several breast cancer cell lines including
MDA-MB-231 and MCF7, and MCF10A, an immortalized
normal mammary epithelial cell line (Figure 1B). qRT-
PCT analysis revealed that the relative transcript level
of UEV1C is approximately 100-fold higher than that of
UEV1A in the above cell lines (Figure 1C), consistent with
observations in other cell lines including HeLa and U2OS
(data not shown).
We next examined relative transcript levels of UEV1A
and UEV1C in breast cancer lines using MCF10A as a
reference. Interestingly, the UEV1A transcript level is ele-
vated in all breast cancer cell lines examined (Figure 1D),
with no significant upregulation of UEV1C (Figure 1E) or
MMS2 (Additional file 2: Figure S1A) in these lines. It has
been previously reported that the UEV1A level may be el-
evated when normal cells undergo immortalization [2]. To
further assess relative UEV1A expression in normal versus
breast tumor tissues, we measured the UEV1A tran-
script level in five normal human breast samples and 43
breast cancer samples from TissueScan microarrays.
Compared with the five normal human breast samples,
33/43 or 77% of breast cancer samples display UEV1A
expression above the highest UEV1A level in normal
samples, or at least 1.7-fold higher than the average level
among the five normal samples (Additional file 2: Figure
S1B), suggesting that Uev1A may play a role in promoting
breast tumorigenesis.
Overexpression of UEV1A promotes breast cancer cell
invasion in vitro and metastasis in a xenograft model
To ask whether an elevated UEV1A level is indeed suffi-
cient to promote breast cancer, UEV1A, UEV1C or MMS2
genes were cloned into a pcDNA4.0/TO/HA(+) vector
and then transfected into MDA-MB-231-TR cells to con-
struct stable cell lines, and the level of ecotopic gene ex-
pression after 10 μg/ml doxycycline (Dox) treatment was
Figure 1 Ubiquitin conjugating enzyme variant (UEV)1A is overexpressed in breast cancer cell lines and tumor samples. (A) Amino acid
sequence alignment of ubiquitin conjugating enzyme variant (Uev)1A, Uev1B, Uev1C and Mms2. Residues critical for the interaction with Ubc13
[9] are indicated with a red box. (B) Uev1 variant protein levels in human breast cancer cell lines. Whole cell extracts were analyzed by western
blotting with the anti-Uev1 monoclonal antibody LN2B [39]. (C) Relative transcript levels of UEV1 variants in human breast cancer cell lines as
determined by qRT-PCR. (D) Relative UEV1A transcript levels in human breast cancer cell lines as determined by qRT-PCR. (E) Relative UEV1C
transcript levels in human breast cancer cell lines as determined by qRT-PCR.
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and western blot against the HA tag (Figure 2A), Uev1
(LN2B, Additional file 2: Figure S2D) or Uev1 plus Mms2
(LN3, Additional file 2: Figure S2E).
The cell growth and cell cycle progression of stable MDA-
MB-231 transfectants were first measured, with no obvi-
ous alterations among each group (Additional file 2:
Figure S3). The effects of ecotopic genes on breast cancer
cell migration and invasion were then measured. Thewound-healing experimental data show that the over-
expression of UEV1A doubles the mobility compared
with the same cells without ecotopic UEV1A expression
or vector-transfected MDA-MB-231-TR cells with Dox
treatment, while overexpression of UEV1C or MMS2 does
not affect cell mobility compared with uninduced cells
(Figure 2B, C and Additional file 2: Figure S4). In a trans-
well assay, the invasiveness of UEV1A transfectants after
induction was approximately 2.3-fold higher than the
Figure 2 UEV1A overexpression promotes breast cancer cell invasion in vitro and metastasis in a xenograft model. (A) pcDNA4.0/TO/HA
(+) vector (CK) expressing UEV1A, UEV1C or MMS2 was stably transfected into MDA-MB-231-TR cells, with or without doxycycline (Dox) treatment.
The level of ectopic gene expression was monitored by western blot against an anti-HA antibody. (B) Representative images of wound-healing
assays with Dox treatment. (C) Statistical analysis of cell migration of wound-healing assay with and without Dox treatment. The migration
distance of cells was measured in five different wells in each group under a light-microscope. (D) Representative images of cell invasion
assay with Matrigel-coated transwells. (E) Statistical analysis of the cell invasion assay data. Cells that invaded the lower surface of the filter were
counted in five random fields under a light-microscope at 200× magnification. (F-I) In vivo tumorigenesis and metastasis assays using a xenograft
mouse model. (F) Lymph node sections after sacrifice were stained with H&E. The lymph node metastasis sites are shown by red arrows. (G) Quantitative
analysis of tumor growth. Tumor growth was measured every week after injection (Day 0) and expressed as mean ± SD (n = 10). (H) The in vivo metastasis
assay in xenograft mice. Upper panel, the lung metastasis nodules formed are shown by red arrows. Lower panel, the lung sections were stained with
H&E and the lung metastasis under a light-microscope at 100× magnification is indicated by a red arrow. (I) Quantitative analysis of the in vivo lung
metastasis as measured by the number of metastasis foci per lung for all four sections (n = 10 mice for each treatment).
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was no significant difference among control, UEV1C and
MMS2 transfectants regardless of Dox treatment (Figure 2D
and E). These results suggest that UEV1A regulates breast
cancer cell migration and invasion in vitro.
As an increased ability of cancer cells to migrate and
invade in vitro is a faithful indicator of cell metastasis, to
further confirm the correlation between UEV1A expres-
sion and breast cancer metastasis, we assessed the effects
of UEV1A on metastasis using an in vivo xenograft mouse
model. Stably-transfected MDA-MB-231-TR cells were
injected into the lateral flanks of 4- to 5-week-old BALB/c
female nude mice and Dox (625 mg/kg) was added in
feed as soon as the cells were injected. Tumor growth
and metastasis were then monitored. All mice (10/10)
injected with the UEV1A-expressing cells had massively
enlarged lymph nodes containing invasive breast cancer
cells (Figure 2F). In contrast, there were no tumor metas-
tasis foci in lymph nodes of mice injected with vector
control or UEV1C-expressing cells, although some lymph
nodes were enlarged (data not shown). Furthermore, over-
expression of UEV1A but not UEV1C accelerated tumor
growth compared to vector-transfected cells (Figure 2G).
In the tail-vein injection groups, compared with UEV1C
or vector control, overexpression of UEV1A significantly
promoted lung metastasis colony fomation (Figure 2H,
and I). These observations collectively demonstrate that
elevated expression of UEV1A alone is sufficient to pro-
mote tumor growth and metastasis.
Depletion of Uev1 prevents breast cancer cell invasion
in vitro and metastasis in nude mice
Compared with MCF-10A cells, there was a 2.7-fold in-
crease in the UEV1A expression in MDA-MB-231 cells
(Figure 1D). To ask whether this moderate overexpression
of UEV1A contributes to breast cancer metastasis, the en-
dogenous UEV1A expression in MDA-MB-231 cells was
suppressed using an shRNA (shUEV1) delivered by lenti-
viral particles. It was found that two independent shUEV1
constructs, shUEV1-1 and shUEV1-2, reduced UEV1A ex-
pression to 40% and 55% of control shRNA-treated cells,
respectively (Figure 3A). As expected, the cellular UEV1C
mRNA and protein levels were also reduced but MMS2
remained unaffected (Additional file 2: Figure S5A-C).
Moreover, partial depletion of Uev1 reduced cell migra-
tion (Figure 3B and Additional file 2: Figure S5D) and in-
vasion (Figure 3C and Additional file 2: Figure S5E). The
above findings were further extended by using a xenograft
lung metastasis model, in which depletion of Uev1 limited
tumor growth to the extent that no tumor was found in
nude mice injected with MDA-MB-231 cells in which the
Uev1 level was reduced by shUEV1-2 (Figure 3D and
Additional file 2: Figure S5F). Furthermore, depletion of
Uev1 in MDA-MB-231 cells significantly reduced thenumber of lung nodules formed in mice and completely
abolished metastasis in lung, even with moderate deple-
tion of Uev1 (Figure 3E, shUEV1-1, middle panel). These
results clearly indicate that the elevated UEV1A expres-
sion in MDA-MB-231 cells plays a critical role in breast
tumorigenesis and metastasis.
Overexpression of UEV1A activates NF-κB in MDA-MB-231
cells in a Ubc13-dependent manner
To understand the mechanism by which Uev1A promotes
metastasis in breast cancer cells, we took into account that
Uev1A has been reported to activate NF-κB in HepG2
[19], and that NF-κB regulates the expression of a large
number of genes critical for tumorigenesis, inflammation
and metastasis [41]. As a hallmark of NF-κB activation is
its translocation from the cytoplasm to the nucleus, we
transfected MDA-MB-231-TR cells with a variety of con-
structs, induced the target gene expression by adding Dox,
fractionated cells and then measured the subcellular distri-
bution of the p65 subunit of NF-κB. As seen in Figure 4A,
only overexpression of UEV1A, but not UEV1C or MMS2,
was able to increase the phosphorylation of the NF-κB
inhibitor IκBα (presumably in the cytoplasm) and en-
rich p65 in the nucleus. Consistently, depletion of Uev1
by shRNA reduced IκBα phosphorylation and p65 nuclear
translocation (Figure 4B).
It has been previously reported that Uev1A is a cofactor
of Ubc13 in the NF-κB signaling pathway [10,17]. To ask
whether the above Uev1A function is indeed dependent
on Ubc13, we created a Uev1A-F38E mutation as the cor-
responding Mms2-F12E mutation (Figure 1A) absolutely
abolishes its interaction with Ubc13 and its ability to pro-
mote Ubc13-mediated K63 polyubiquitination [9]. Indeed
we confirmed that the Uev1A-F38E substitution does not
affect its expression (Additional file 2: Figure S2F) but
abolishes its interaction with Ubc13 in vivo (Figure 4C).
As expected, overexpression of UEV1A-F38E failed to ac-
tivate NF-κB, as judged by a lack of IκBα phosphorylation
and p65 nucleaar translocation (Figure 4D).
MMP1 and MMP9 are tightly regulated by UEV1
As NF-κB is a transcriptional factor that regulates the
expression of a large number of genes including those
involved in metastasis, we measured the transcription of
many established or putative NF-κB target genes thought
to be involved in metastasis such as COX2 [42], VEGF
[43] and MMP family genes, among which MMP1 and
MMP9 transcripts were elevated by 4.6- and 3.9-fold, re-
spectively, in UEV1A-overexpression cells, but not in UEV1C
or MMS2 overexpression cells (Figure 5A,B), with corre-
sponding elevation at proteins levels (Figure 5C). The
observed increase is completely dependent on Ubc13,
as overexpression of UEV1A-F38E failed to induce
MMP1 or MMP9 (Figure 5B). Similarly, depletion of
Figure 3 Depletion of ubiquitin conjugating enzyme variant (Uev)1 reduces cell invasion in vitro and metastasis in a xenograft mouse
model. (A) MDA-MB-231 cells were transfected with shRNA lentiviral particles against UEV1 (shUEV1) or non-specific target (shCK). shUEV1-1
and shUEV1-2 represent two independent stable shUEV1 lines. UEV1A transcript levels in shCK and shUEV1 lines were determined by qRT-PCR.
(B) Quantitative analysis of cell migration by wound-healing assay. The migration distance of cells was measured in five different wells in each
treatment group under a light-microscope. (C) Quantitative analysis of cell invasion in Matrigel-coated transwells. Cells invading the lower surface
of the filter were counted in five random fields under a light-microscope at 200× magnification. (D, E) The in vivo tumorigenesis assay using a
xenograft mouse model. 1 × 106 MDA-MB-231 cells depleted with shUEV1 or shCK were injected into the lateral flanks of 4- to 5-week-old BALB/c
female nude mice. (D) Tumor growth was measured every week after injection (Day 0) and expressed as mean ± SD (n = 10). (E) Upper panel,
lungs from mice injected via tail veins with MDA-MB-231 cells treated with shUEV1s or control. Red arrows point to lung metastasis foci. Middle
panel, quantitative analysis of the number of metastasis foci per lung. The nodules per lung for all four sections were counted under a light-microscope
(×100) (n = 10 mice for each treatment). Lower panel, sample lung sections stained with H&E. Red arrows point to lung metastasis foci. All samples
were taken after sacrifice.
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and MMP9 transcript (Figure 5D) and protein (Figure 5E)
levels, and more efficient depletion of UEV1 (shUEV1-1
versus shUEV1-2) resulted in stronger repression of
MMP1 and MMP9 expression (Figure 5D and E), in-
dicating that MMP1 and MMP9 are tightly regulated
by Uev1A-Ubc13.MMP1 is a downstream effector for Uev1A-induced
metastasis
To ask whether MMP1 and/or MMP9 are critical ef-
fectors for Uev1A-induced metastasis, we depletedMMP1
or MMP9 by siRNA in MDA-MB-231 cells (Figure 6A).
The above treatment did not affect the UEV1A expression
(Figure 6A), but the depletion of MMP1 significantly
Figure 4 Ubiquitin conjugating enzyme variant (Uev)1A activates NF-κB in MDA-MB-231 cells in a Ubc13-dependent manner. (A) NF-κB
activation in UEV-overexpressing cells. Nuclear or whole-cell extracts were prepared, equal amounts of protein were separated by SDS–PAGE gel,
followed by western blotting analysis using an anti-p65 antibody to measure NF-кB nuclear enrichment and an anti-P(S32)-inhibitor of NF-κBα
(IκBα) antibody to assess the degree of IκBα phosphorylation as an indication of its degradation and release of NF-κB into the nucleus. (B) NF-κB
activation in Uev1-depleted cells. Experimental conditions are as described in Figure 4A. (C) The F38 residue of Uev1A was required for its interaction
with Ubc13. MDA-MB-231 cell extracts expressing UEV1A or UEV1A-F38E were immunoprecipitated with an anti-HA monoclonal antibody, followed by
western blotting with an anti-Ubc13 monoclonal antibody and an anti-HA monoclonal antibody. (D) Uev1A-F38E failed to activate NF-κB. Experimental
conditions were as described in Figure 4A.
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termined by a transwell assay, while MMP9 depletion
had much less effect (Figure 6B and Additional file 2:
Figure S6A). Similarly, MMP1 depletion in UEV1A-
overexpressed MDA-MB-231 cells (Additional file 2:
Figure S6B) also decreased invasiveness (Additional file 2:
Figure S6C and D). To ask whether overexpression of
MMP1 is indeed sufficient to dictate MDA-MB-231 cell
invasion, we constructed an MMP1-expression plasmid
and transfected it to MDA-MB-231 cells, which re-
sulted in a 2.6-fold increase in the MMP1 transcript level
(Additional file 2: Figure S6E) and a similar increase at the
protein level (Additional file 2: Figure S6F), as well as a
2.3-fold increase in invasion (Figure 6C and Additional
file 2: Figure S6G). We then restored MMP1 level in
UEV1-depleted cells to that of control cells (Figure 6D
and E), which was sufficient to rescue the invasiveness in
both UEV1-depleted MDA-MB-231 cell lines (Figure 6F).
As MMP1 is an important cancer cell metastasis factor[44-46], the above findings allow us to conclude that
UEV1A regulates metastasis through tightly controlling
MMP1 expression.
UevA-Ubc13 control MMP1 expression by regulating NF-κB
To ask whether Uev1A regulates MMP1 through NF-κB,
we cloned the 1.8-kb human MMP1 promoter sequence
(Figure 7A) into pGL4.2 and co-transfected it with plas-
mids expressing UEV1A, UEV1A-F38E or an empty vector
into MDA-MB-231 cells. A luciferase assay showed that
UEV1A expression activates theMMP1 promoter and that
this activation relies on its interaction with Ubc13, as the
Uev1A-F38E substitution completely abolished the activa-
tion (Figure 7B). The predicted NF-κB binding site (−1133
to approximately −1125) in the MMP1 promoter was then
mutated (Figure 7A) and the mutated reporter was used
to co-transfect with plasmids expressing UEV1A, UEV1C,
MMS2 or the empty vector into MDA-MB-231 cells. Over-
expression of only UEV1A, but not UEV1C or MMS2,
Figure 5 Ubiquitin conjugating enzyme variant (Uev)1A positively regulates MMP1 and MMP9 expression. (A) The transcript levels of
selected putative NF-κB target genes in MDA-MB-231-TR cells expressing different UEVs as determined by qRT-PCR. (B) Overexpression of UEV1A
but not UEV1A-F38E stimulated MMP1 and MMP9 expression in MDA-MB-231 cells as determined by qRT-PCR. (C) Elevated MMP1 and MMP9
protein levels in UEV1A-overexpressed MDA-MB-231 cells as determined by western blot. (D) The transcript levels of MMP1 and MMP9 in two
independent shUEV1-transfected MDA-MB-231 cell lines as determined by qRT-PCR. (E) MMP1 and MMP9 protein levels in two independent
shUEV1-transfected MDA-MB-231 cell lines as determined by western blot.
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activation absolutely required the intact NF-κB target
site (Figure 7C). To gain direct evidence that the predicted
NF-κB binding site indeed interacts with NF-κB, an EMSA
was performed using nuclear lysates from TNFα-treated
and untreated cells (Figure 7D). A biotin-labeled syntheticMMP1 promoter probe containing the putative NF-κB-
binding sequence was able to interact with the nuclear
lysate and this interaction was enhanced when cells were
pretreated with TNF-α, which induced nuclear transloca-
tion of p65 (Figure 7E, lanes 4 and 5). This interaction
was abolished when the NF-κB binding sequence was
Figure 6 Matrix metalloproteinase (MMP)1 is a downstream effector for ubiquitin conjugating enzyme variant (Uev)1A-induced
metastasis. (A) The mRNA levels of MMP1, MMP9 and UEV1A in MMP1 or MMP9 knocked-down MDA-MB-231 cells as determined by qRT-PCR.
(B) Quantitative analysis of cell invasive ability in Matrigel-coated transwells. MDA-MB-231 cells depleted of MMP1 or MMP9 were subject to the
transwell assay and at least five random fields were counted under a light-microscope at 200× magnification. (C) Quantitative analysis of cell
invasive ability in Matrigel-coated transwells. MDA-MB-231 cells overexpressing MMP1 were subject to the transwell assay and at least five random
fields were counted under a light-microscope at 200× magnification. (D) Ectopic expression of MMP1 restored the MMP1 transcript level in two
independent UEV1-depleted cell lines as determined by qRT-PCR. (E) Ectopic expression of MMP1 restored the MMP1 protein level in two
independent UEV1-depleted cell lines as determined by western blot. (F) Quantitative analysis of cell invasive ability in Matrigel-coated
transwells. At least five random fields were counted under a light-microscope at 200× magnification.
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labeled probe (lane 7), indicating that the interaction is
sequence-specific. We conclude from the above observa-
tions that NF-κB directly binds to the MMP1 promoter at
the predicted binding site.Discussion
It has been reported previously that human cells contain
two UEV genes, UEV1 and MMS2, which share >90%
amino acid sequence-identity in their core domains [4].
Although both Uev1A and Mms2 proteins serve as
Figure 7 Ubiquitin conjugating enzyme variant (Uev)1A regulates Matrix metalloproteinase 1 (MMP1) expression through an NF-κB
target sequence in the MMP1 promoter. (A) A schematic illustration of the MMP1 promoter and the PMMP1-Luciferase (Luc) reporter construct.
A putative NF-κB binding site in the MMP1 promoter [GenBank: AJ002550.1] is mapped to 1133–1125 nucleotides upstream of its start codon.
The mutated sequence in the PMMP1-NF-κBm construct is also shown. (B) The PMMP1-Luc reporter was co-transfected to MDA-MB-231 cells with
constructs that overexpressed wild-type UEV1A or UEV1A-F38E. The data were normalized to the activity of cells transfected with the empty vector
(pGL4.2). (C) Only UEV1A, but not UEV1C or hMMS2, was able to activate the MMP1 promoter, and this ability was dependent on its interaction
with Ubc13. The experimental conditions were as described in Figure 7B. (D) TNFα activates NF-κB as measured by the nuclear localization of the
p65 subunit of NF-κB. HeLa cells were treated with or without TNFα for 30 minutes, nuclear proteins were purified and the relative p65 level in
the nuclear fraction was determined by western blot and the nuclear protein Lamin B was used as a loading control. (E) Physical interaction
between NF-κB and the putative NF-κB target sequence in the MMP1 promoter as determined by electrophoretic mobility shift assay. Lane 1, biotin-
labeled NF-κB target sequence probe (NF-κB*). Lane 2, biotin-labeled mutated NF-κB binding site probe (NF-κBm*). Lane 3, Unlabeled double-strand
DNA containing the PMMP1 NF-κB target sequence (NF-κB). Lanes 4 to 7 contain either wild-type or mutated PMMP1 NF-κB target sequence as indicated
in the upper panel, plus TNFα-treated or untreated cell extract. Lane 7 also contains excessive unlabeled DNA of PMMP1 NF-κB target sequence.
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nation, their biological functions are apparently distinct
and only the Uev1A-Ubc13 complex is involved in NF-κB
signaling [10]. It has been puzzling us that Uev1A and
Mms2 have different molecular weights and migrate
differently; however, a monoclonal antibody capable ofrecognizing both purified Uev1A and Mms2 only detects
a single band in western blot analysis, and siRNA deple-
tion of either Mms2 or Uev1 only partially reduced the in-
tensity of this band. A careful examination in this study
reveals that in addition to the previously reported two
UEV1 splicing variants UEV1A and UEV1B [1], cultured
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lacking the N-terminal 30 amino acid unique region of
Uev1A. The resulting 147-residue protein would co-
migrate with Mms2 during electrophoresis. It turns out
that the UEV1C transcript is much more abundant than
UEV1A, and a Uev1-specific monoclonal antibody can de-
tect cellular Uev1C but not Uev1A, unless the latter is ex-
perimentally overexpressed.
The current study investigates roles of UEV1A, UEV1C
and MMS2 in tumorigenesis using a breast cancer model.
With comparable levels of ectopic expression, it was
found that only UEV1A, but not UEV1C or MMS2, is able
to promote cell migration and invasion. Similarly, overex-
pression of UEV1A, but not UEV1C promotes tumor
growth and metastasis in a xenograft mouse model. The
above results are highly reliable, as the target gene expres-
sion is under tight regulation of a Tet-on promoter, and
the phenotypes were only observed under Dox-induced
conditions. In a reverse experiment, depletion of Uev1 in
cultured breast cancer cells significantly reduces cell mi-
gration and invasion, as well as tumor growth and metas-
tasis in a dose-dependent manner, indicating that the
cellular Uev1 (presumbly Uev1A) level plays a critical role
in breast tumorigenesis and metastasis.
To understand the molecular mechanism by which
Uev1A promotes tumorigenesis, we demonstrated that
overexpression of UEV1A, but not UEV1C or MMS2, is
able to promote IκBα phorsphorylation and NF-κB trans-
location into the nucleus, and that this effect absolutely re-
lies on its physical interaction with Ubc13. It is conceivable
that as previously reported, the Ubc13-Uev1A heteromider
serves as an E2 to assemble K63-linked poly-Ub chains
along with cognate really interesting new gene (RING)-
finger E3s like TRAF2 and/or TRAF6 [17,34], which
recruit K63 polyUb-binding proteins like NEMO [18]
and TAB2/3 [47,48] to phorsphorylate and subsequently
degrade IκBα, leading to NF-κB activation.
NF-κB activation promotes the transcription of many
downstream genes in the signaling cascade [41]. However,
the moderate level of NF-κB activation by UEV1A overex-
pression does not appear to induce all NF-κB targeting
genes. To understand how overexpression of UEV1A leads
to tumorigenesis and particularly metastasis in breast can-
cer cells, we surveyed NF-κB and metastasis-related genes
and focused on two candidate genes, MMP1 and MMP9,
both of which are highly induced upon UEV1A overex-
pression. Experimental results as presented in this report
indicate that both genes are tightly regulatd by cellular
Uev1 levels; however, depletion of MMP9 was not as ef-
fective as that of MMP1 on cell migration and invasion.
As ecotopic expression of MMP1 to restore the wild-type
level in Uev1-depleted cells also restored wild-type level
of invasiveness, it is plausible to conclude that MMP1
is the critical downstream effector of UEV1A-inducedbreast cancer metastasis, although this study does not rule
out the contributions of MMP9 and possibly other genes.
The signal transduction cascade of Uev1A→NF-κB→
MMP1→metastasis is further confirmed by showing that
Uev1A-induced MMP1 expression is dependent on both
Ubc13 and the predicted NF-κB binding site located in
the MMP1 promoter. Although this report only presents
data from one human breast cancer line, we have obtained
comparable results with a different breast cancer cell line
MCF7 (data not shown), indicating that the tumorigenic
and metastatic effects of Uev1A is a general phenomenon
in breast cancers.
While the experimental evidence as shown in this report
clearly indicates that UEV1A can function as a proto-
oncogene, the clinical relevance of this finding awaits fu-
ture investigation. Nevertheless, our limited TissueScan
microarray data indicate a low (less than 2-fold) variation
in UEV1A transcript levels among five normal human
breast samples, compared with an increase of up to 20-
fold in some breast cancer samples. As NF-κB activation is
commonly observed in breast cancers [24,25,49] and
UEV1 upregulation is also frequently observed in breast
cancer samples [12-14] and in cultured tumor cell lines
[4], and is found to be correlated to tumorigenic indicators
[2,3], it is conceivable that a certain percentage of breast
cancer samples with NF-κB activation is due to elevated
UEV1A expression.
This study demonstrated that the N-terminal region of
Uev1A is the molecular determinant of its cellular func-
tion(s) in the NF-κB signaling pathway. Although the
exact cellular function of Uev1C remains a mystery, our
previous studies [10] have shown that truncated Uev1A
missing the N-terminal 30 amino acids behaves like
Mms2 in terms of subcellular localization and promo-
tion of K63-linked di-Ub versus poly-Ub chains in vitro,
suggesting that Uev1C may play an Mms2-related role.
Given the importance of Uev1 in signaling and tumori-
genesis, small-molecule inhibitors against Uev1 have been
isolated [20,50] based on their interference with the Ubc13-
Uev1A interaction, and one appears to be able to inhibit
proliferation and survival of diffuse large B-cell lymphoma
cells. It is unclear whether these inhibitors also interfere
with the Ubc13-Mms2 interaction, as critical residues
responaible for the heterdimer formation are conserved be-
tween Uev1 and Mms2 [9]. Furthermore, this study pro-
vides evidence that a desired inhibitor should target the
N-terminal region of Uev1A instead of the Ubc13-Uev1
interface. Hence, this report provides an experimental and
theoretical cornerstone for future diagnosis and therapy
by targeting Uev1A for the cure of breast cancer.
Conclusions
Among three Uev gene products, only Uev1A promotes
breast tumor metastasis, which is primarily through
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is considered a proto-oncogene and a therapeutic target
for breast cancers.
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